NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
59 hedge funds and large institutions have $155M invested in NKGen Biotech, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 10 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
11% more funds holding
Funds holding: 53 → 59 (+6)
9% more capital invested
Capital invested by funds: $143M → $155M (+$12.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
+$6.18M |
| 2 |
CIM
Cowen Investment Management
New York
|
+$5.43M |
| 3 |
Jane Street
New York
|
+$4.95M |
| 4 |
CAC
Cowen and Company
New York
|
+$3.59M |
| 5 |
JP Morgan Chase
New York
|
+$3.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$11.9M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$7.33M |
| 3 |
SCM
Saba Capital Management
New York
|
-$4.05M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$3.12M |
| 5 |
FTCM
Fir Tree Capital Management
New York
|
-$2.06M |
NKGN Hedge Fund Activity: Q4 2022 in Review
59 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q4 2022, worth a combined $155M — up 9% from $143M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new NKGN positions and 10 closed out — a net gain of 6 holders — while 13 added to existing stakes and 6 trimmed.
The largest buyer was Sandia Investment Management, opening a new position worth an estimated $6.18M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $11.9M sold.
- 59 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q4 2022, up from 53 in Q3 2022.
- Funds reported $155M of NKGen Biotech, Inc. Common Stock stock for Q4 2022, up 9% quarter-over-quarter.
- 16 funds opened new NKGen Biotech, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of +6 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q4 2022 was Sandia Investment Management, an estimated $6.18M added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q4 2022 was Highbridge Capital Management, an estimated $11.9M sold.
Based on aggregated 13F filings for Q4 2022.